MRGPRX2 and inflammatory bowel disease: However, there are no studies focused on mast cell Ca2+ signalling in IBD; only one paper has it been reported that MRGPRX2 (a mast cell predominant G-protein-coupled receptor) activation leads to calcium mobilization in mast cells, which is a key step in MC degranulation and release of inflammatory mediators, which can contribute to inflammation in UC, suggesting that blocking MRGPRX2 signalling could be a potential therapeutic strategy for treating UC by reducing MC activation and inflammation [51].